- Home
- KMDA vs CDXS Comparison
KMDA vs CDXS Comparison
Compare KMDA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- CDXS
- Stock Information
- Founded
- KMDA 1990
- CDXS 2002
- Country
- KMDA Israel
- CDXS United States
- Employees
- KMDA N/A
- CDXS N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- KMDA Health Care
- CDXS Industrials
- Exchange
- KMDA Nasdaq
- CDXS Nasdaq
- Market Cap
- KMDA 349.6M
- CDXS 332.0M
- IPO Year
- KMDA N/A
- CDXS 2010
- Fundamental
- Price
- KMDA $5.87
- CDXS $5.63
- Analyst Decision
- KMDA Strong Buy
- CDXS Buy
- Analyst Count
- KMDA 2
- CDXS 2
- Target Price
- KMDA $14.50
- CDXS $11.00
- AVG Volume (30 Days)
- KMDA 30.2K
- CDXS 691.3K
- Earning Date
- KMDA 11-13-2024
- CDXS 10-31-2024
- Dividend Yield
- KMDA N/A
- CDXS N/A
- EPS Growth
- KMDA 124.29
- CDXS N/A
- EPS
- KMDA 0.27
- CDXS N/A
- Revenue
- KMDA $158,380,000.00
- CDXS $64,446,000.00
- Revenue This Year
- KMDA $15.38
- CDXS N/A
- Revenue Next Year
- KMDA $6.18
- CDXS $2.02
- P/E Ratio
- KMDA $21.16
- CDXS N/A
- Revenue Growth
- KMDA 4.52
- CDXS N/A
- 52 Week Low
- KMDA $4.74
- CDXS $2.53
- 52 Week High
- KMDA $6.53
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- KMDA 52.31
- CDXS 71.90
- Support Level
- KMDA $5.71
- CDXS $5.42
- Resistance Level
- KMDA $5.90
- CDXS $6.01
- Average True Range (ATR)
- KMDA 0.16
- CDXS 0.33
- MACD
- KMDA -0.03
- CDXS 0.03
- Stochastic Oscillator
- KMDA 40.35
- CDXS 69.68
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.